Nanocovax vaccine clinical trial to be started on December 17.
The volunteers for the first phase must be healthy people from 18 to 50 years old. They must understand the process and sign an agreement to join the trial. They must not have any acute or chronic illnesses and indicators related to haematology and biochemistry must be normal.
On October 9, the National Ethics Committee in Biomedical Research held a review meeting and approved the clinical trial plan for Nanocovax vaccines produced by Nanogen Company. The number of volunteers and criteria for the trials were also approved by the National Ethics Committee in Biomedical Research.
60 volunteers will be divided into three groups. The first group will be given a dose of 25mcg per person, the second group will be given 50mcg and 75mcg for the third group. Each person will be given two shots, each shot will be 28 days apart.
The dose will be increased incrementally in order to ensure safety for the volunteers.
The first step will be carried out with three people. After 72 hours, the results will be reviewed and the trial will be continued with more volunteers.